Research programme: type II DNA topoisomerase inhibitors - Nox Pharmaceuticals
Alternative Names: Adva-32a; Carbon-difluoro etoposide derivatives - Advanomics/Sunshine Biopharma; Difluoro-Etoposide; Topo2 inhibitors - Advanomics/Sunshine Biopharma; Topoisomerase II inhibitors - Advanomics/Sunshine BiopharmaLatest Information Update: 28 May 2020
At a glance
- Originator Advanomics
- Developer NOX Pharmaceuticals
- Class Antineoplastics; Dioxanes; Dioxolanes; Lactones; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Cancer; Pancreatic cancer; Small cell lung cancer; Uterine cancer
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Breast-cancer in Canada (PO, Capsule)
- 28 May 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO, Capsule)
- 28 May 2020 No recent reports of development identified for preclinical development in Pancreatic-cancer in Canada (PO, Capsule)